;PMID: 9234831
;source_file_852.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..219] = [t:49..219]
;2)section:[e:223..234] = [t:223..234]
;3)section:[e:238..424] = [t:238..424]
;4)sentence:[e:428..577] = [t:428..577]
;5)sentence:[e:578..699] = [t:578..699]
;6)sentence:[e:700..982] = [t:700..982]
;7)sentence:[e:983..1209] = [t:983..1209]
;8)sentence:[e:1211..1506] = [t:1211..1506]
;9)sentence:[e:1507..1688] = [t:1507..1688]
;10)sentence:[e:1689..1938] = [t:1689..1938]
;11)sentence:[e:1939..2114] = [t:1939..2114]
;12)sentence:[e:2115..2177] = [t:2115..2177]
;13)sentence:[e:2178..2598] = [t:2178..2598]
;14)section:[e:2602..2646] = [t:2602..2646]

;section 0 Span:0..43
;Am J Hypertens. 1997 Jul;10(7 Pt 1):763-71.
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..14] Hypertens) (.:[14..15] .)
        (CD:[16..20] 1997) (CC:[21..28] Jul;10-LRB-) (CD:[28..29] 7)
        (NN:[30..32] Pt) (.:[33..34] 1) (-RRB-:[34..35] -RRB-)
        (CD:[35..39] :763) (::[39..40] -) (CD:[40..42] 71) (.:[42..43] .)))

;sentence 1 Span:49..219
;Endothelium-derived hyperpolarizing factor: characterization as a cytochrome 
;P450 1A-linked metabolite of arachidonic acid in perfused rat mesenteric 
;prearteriolar bed.
;[49..91]:substance:"Endothelium-derived hyperpolarizing factor"
;[115..134]:cyp450:"cytochrome  P450 1A"
;[142..152]:substance:"metabolite"
;[156..172]:substance:"arachidonic acid"
(SENT
  (NP-HLN
    (NP
      (ADJP (NN:[49..60] Endothelium) (HYPH:[60..61] -) (VBN:[61..68] derived))
      (VBG:[69..84] hyperpolarizing) (NN:[85..91] factor))
    (::[91..92] :)
    (NP
      (NP (NN:[93..109] characterization))
      (PP (IN:[110..112] as)
        (NP
          (NP (DT:[113..114] a)
            (ADJP
              (NML (NN:[115..125] cytochrome) (NN:[127..131] P450)
                   (NN:[132..134] 1A))
              (HYPH:[134..135] -) (VBN:[135..141] linked))
            (NN:[142..152] metabolite))
          (PP (IN:[153..155] of)
            (NP (JJ:[156..167] arachidonic) (NN:[168..172] acid)))))
      (PP (IN:[173..175] in)
        (NP (JJ:[176..184] perfused) (NN:[185..188] rat)
            (JJ:[189..199] mesenteric) (JJ:[201..214] prearteriolar)
            (NN:[215..218] bed))))
    (.:[218..219] .)))

;section 2 Span:223..234
;Adeagbo AS.
(SEC
  (FRAG (NNP:[223..230] Adeagbo) (NNP:[231..233] AS) (.:[233..234] .)))

;section 3 Span:238..424
;Department of Physiology and Biophysics and the Center of Excellence in
;Applied  Microcirculatory Research, University of Louisville, Kentucky 40292,
;USA.  ASADEA01@ulkyvm.louisville.edu
(SEC
  (FRAG (NNP:[238..248] Department) (IN:[249..251] of)
        (NNP:[252..262] Physiology) (CC:[263..266] and)
        (NNP:[267..277] Biophysics) (CC:[278..281] and) (DT:[282..285] the)
        (NNP:[286..292] Center) (IN:[293..295] of) (NNP:[296..306] Excellence)
        (IN:[307..309] in) (NNP:[310..317] Applied)
        (NNP:[319..335] Microcirculatory) (NNP:[336..344] Research)
        (,:[344..345] ,) (NNP:[346..356] University) (IN:[357..359] of)
        (NNP:[360..370] Louisville) (,:[370..371] ,) (NNP:[372..380] Kentucky)
        (NN:[381..386] 40292) (IN:[386..387] ,) (NNP:[388..391] USA)
        (.:[391..392] .) ('':[394..409] ASADEA01@ulkyvm)
        (VBD:[409..420] .louisville) (.:[420..424] .edu)))

;sentence 4 Span:428..577
;The isolated perfused rat mesenteric bed releases endothelium-derived 
;hyperpolarizing factor (EDHF) in response to acetylcholine (ACh) or
;histamine.
;[478..521]:substance:"endothelium-derived  hyperpolarizing factor"
;[523..527]:substance:"EDHF"
;[544..557]:substance:"acetylcholine"
;[559..562]:substance:"ACh"
;[567..576]:substance:"histamine"
(SENT
  (S
    (NP-SBJ (DT:[428..431] The) (JJ:[432..440] isolated)
            (JJ:[441..449] perfused) (NN:[450..453] rat)
            (JJ:[454..464] mesenteric) (NN:[465..468] bed))
    (VP (VBZ:[469..477] releases)
      (NP
        (NP
          (ADJP (NN:[478..489] endothelium) (HYPH:[489..490] -)
                (VBN:[490..497] derived))
          (VBG:[499..514] hyperpolarizing) (NN:[515..521] factor))
        (NP (-LRB-:[522..523] -LRB-) (NN:[523..527] EDHF)
            (-RRB-:[527..528] -RRB-)))
      (PP (IN:[529..531] in)
        (NP
          (NP (NN:[532..540] response))
          (PP (TO:[541..543] to)
            (NP
              (NP
                (NP (NN:[544..557] acetylcholine))
                (NP (-LRB-:[558..559] -LRB-) (NN:[559..562] ACh)
                    (-RRB-:[562..563] -RRB-)))
              (CC:[564..566] or)
              (NP (NN:[567..576] histamine)))))))
    (.:[576..577] .)))

;sentence 5 Span:578..699
;I  propose that EDHF released in the mesenteric vascular bed is a cytochrome
;P450  (CYP)-linked, arachidonate metabolite.
;[594..598]:substance:"EDHF"
;[644..659]:cyp450:"cytochrome P450"
;[662..665]:cyp450:"CYP"
;[675..698]:substance:"arachidonate metabolite"
(SENT
  (S
    (NP-SBJ (PRP:[578..579] I))
    (VP (VBP:[581..588] propose)
      (SBAR (IN:[589..593] that)
        (S
          (NP-SBJ
            (NP (NN:[594..598] EDHF))
            (VP (VBN:[599..607] released)
              (NP (-NONE-:[607..607] *))
              (PP-LOC (IN:[608..610] in)
                (NP (DT:[611..614] the) (JJ:[615..625] mesenteric)
                    (JJ:[626..634] vascular) (NN:[635..638] bed)))))
          (VP (VBZ:[639..641] is)
            (NP-PRD (DT:[642..643] a)
              (ADJP
                (NML
                  (NML (NN:[644..654] cytochrome) (NN:[655..659] P450))
                  (NML (-LRB-:[661..662] -LRB-) (NN:[662..665] CYP)
                       (-RRB-:[665..666] -RRB-)))
                (HYPH:[666..667] -) (VBN:[667..673] linked))
              (,:[673..674] ,)
               (NN:[675..687] arachidonate) (NN:[688..698] metabolite))))))
    (.:[698..699] .)))

;sentence 6 Span:700..982
;In the presence of nitro-L-arginine  methyl ester (L-NAME) and indomethacin,
;injections of ACh (0.001 to 10 nmol) or  histamine (0.1 to 1,000 nmol)
;elicited transient, dose-dependent dilation of  cirazoline (an
;alpha1-adrenoceptor selective agonist) preconstricted mesenteric  beds.
;[719..749]:substance:"nitro-L-arginine  methyl ester"
;[751..757]:substance:"L-NAME"
;[763..775]:substance:"indomethacin"
;[791..794]:substance:"ACh"
;[796..807]:quantitative-value:"0.001 to 10"
;[808..812]:quantitative-units:"nmol"
;[818..827]:substance:"histamine"
;[829..841]:quantitative-value:"0.1 to 1,000"
;[842..846]:quantitative-units:"nmol"
;[896..906]:substance:"cirazoline"
;[911..930]:substance:"alpha1-adrenoceptor"
;[941..948]:substance:"agonist"
(SENT
  (S
    (PP-LOC (IN:[700..702] In)
      (NP
        (NP (DT:[703..706] the) (NN:[707..715] presence))
        (PP (IN:[716..718] of)
          (NP
            (NP
              (NP (NN:[719..735] nitro-L-arginine) (NN:[737..743] methyl)
                  (NN:[744..749] ester))
              (NP (-LRB-:[750..751] -LRB-) (NN:[751..757] L-NAME)
                  (-RRB-:[757..758] -RRB-)))
            (CC:[759..762] and)
            (NP (NN:[763..775] indomethacin))))))
    (,:[775..776] ,)
    (NP-SBJ
      (NP (NNS:[777..787] injections))
      (PP (IN:[788..790] of)
        (NP
          (NP
            (NP (NN:[791..794] ACh))
            (PRN (-LRB-:[795..796] -LRB-)
              (NP
                (QP (CD:[796..801] 0.001) (TO:[802..804] to) (CD:[805..807] 10))
                (NN:[808..812] nmol))
              (-RRB-:[812..813] -RRB-)))
          (CC:[814..816] or)
          (NP (NN:[818..827] histamine)
            (PRN (-LRB-:[828..829] -LRB-)
              (NP
                (QP (CD:[829..832] 0.1) (TO:[833..835] to) (CD:[836..841] 1,000))
                (NN:[842..846] nmol))
              (-RRB-:[846..847] -RRB-))))))
    (VP (VBD:[848..856] elicited)
      (NP
        (NP (JJ:[857..866] transient) (,:[866..867] ,)
          (ADJP (NN:[868..872] dose) (HYPH:[872..873] -)
                (JJ:[873..882] dependent))
          (NN:[883..891] dilation))
        (PP (IN:[892..894] of)
          (NP
            (ADJP
              (NML
                (NML (NN:[896..906] cirazoline))
                (NML (-LRB-:[907..908] -LRB-) (DT:[908..910] an)
                  (ADJP (NN:[911..930] alpha1-adrenoceptor)
                        (JJ:[931..940] selective))
                  (NN:[941..948] agonist) (-RRB-:[948..949] -RRB-)))
              (JJ:[950..964] preconstricted))
            (JJ:[965..975] mesenteric) (NNS:[977..981] beds)))))
    (.:[981..982] .)))

;sentence 7 Span:983..1209
;The L-NAME-resistant responses to ACh or histamine were insensitive to 
;tetrodotoxin (1 micromol/L), thus negating its neuronal origin, but were 
;profoundly attenuated by a K+ channel inhibitor tetrabutylammonium (0.5
;mmol/L).
;[987..993]:substance:"L-NAME"
;[1017..1020]:substance:"ACh"
;[1024..1033]:substance:"histamine"
;[1055..1067]:substance:"tetrodotoxin"
;[1069..1070]:quantitative-value:"1"
;[1071..1081]:quantitative-units:"micromol/L"
;[1156..1158]:substance:"K+"
;[1167..1176]:substance:"inhibitor"
;[1177..1195]:substance:"tetrabutylammonium"
;[1197..1200]:quantitative-value:"0.5"
;[1201..1207]:quantitative-units:"mmol/L"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[983..986] The)
        (ADJP (NN:[987..993] L-NAME) (HYPH:[993..994] -)
              (JJ:[994..1003] resistant))
        (NNS:[1004..1013] responses))
      (PP (TO:[1014..1016] to)
        (NP (NN:[1017..1020] ACh) (CC:[1021..1023] or)
            (NN:[1024..1033] histamine))))
    (VP
      (VP (VBD:[1034..1038] were)
        (ADJP-PRD (JJ:[1039..1050] insensitive)
          (PP (TO:[1051..1053] to)
            (NP
              (NP (NN:[1055..1067] tetrodotoxin))
              (PRN (-LRB-:[1068..1069] -LRB-)
                (NP
                  (NP (CD:[1069..1070] 1) (NN:[1071..1079] micromol))
                  (PP (SYM:[1079..1080] /)
                    (NP (NN:[1080..1081] L))))
                (-RRB-:[1081..1082] -RRB-)))))
        (,:[1082..1083] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1083..1083] *))
          (VP
            (ADVP (RB:[1084..1088] thus))
            (VBG:[1089..1097] negating)
            (NP (PRP$:[1098..1101] its) (JJ:[1102..1110] neuronal)
                (NN:[1111..1117] origin)))))
      (,:[1117..1118] ,) (CC:[1119..1122] but)
      (VP (VBD:[1123..1127] were)
        (VP
          (ADVP (RB:[1129..1139] profoundly))
          (VBN:[1140..1150] attenuated)
          (NP-1 (-NONE-:[1150..1150] *))
          (PP (IN:[1151..1153] by)
            (NP-LGS
              (NP
                (NP (DT:[1154..1155] a)
                  (NML (NN:[1156..1157] K) (SYM:[1157..1158] +))
                  (NN:[1159..1166] channel) (NN:[1167..1176] inhibitor))
                (NP (NN:[1177..1195] tetrabutylammonium)))
              (PRN (-LRB-:[1196..1197] -LRB-)
                (NP
                  (NP (CD:[1197..1200] 0.5) (NN:[1201..1205] mmol))
                  (PP (SYM:[1205..1206] /)
                    (NP (NN:[1206..1207] L))))
                (-RRB-:[1207..1208] -RRB-)))))))
    (.:[1208..1209] .)))

;sentence 8 Span:1211..1506
;7-Ethoxyresorufin (a selective and competitive blocker of CYP 1A isozyme) 
;blunted ACh and histamine mediated EDHF responses but did not alter
;vasodilation  initiated through K+ channel activation by either cromakalim or
;NS-1619, or  through the nitric oxide-cGMP pathway (sodium nitroprusside).
;[1211..1228]:substance:"7-Ethoxyresorufin"
;[1258..1265]:substance:"blocker"
;[1269..1283]:cyp450:"CYP 1A isozyme"
;[1294..1297]:substance:"ACh"
;[1302..1311]:substance:"histamine"
;[1321..1325]:substance:"EDHF"
;[1386..1388]:substance:"K+"
;[1418..1428]:substance:"cromakalim"
;[1432..1439]:substance:"NS-1619"
;[1457..1469]:substance:"nitric oxide"
;[1470..1474]:substance:"cGMP"
;[1484..1504]:substance:"sodium nitroprusside"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1211..1228] 7-Ethoxyresorufin))
      (NP (-LRB-:[1229..1230] -LRB-)
        (NP (DT:[1230..1231] a)
          (NML
            (NML (JJ:[1232..1241] selective)
              (NML-3 (-NONE-:[1241..1241] *P*)))
            (CC:[1242..1245] and)
            (NML (JJ:[1246..1257] competitive)
              (NML-3 (NN:[1258..1265] blocker)))))
        (PP (IN:[1266..1268] of)
          (NP
            (NML (NN:[1269..1272] CYP) (NN:[1273..1275] 1A))
            (NN:[1276..1283] isozyme)))
        (-RRB-:[1283..1284] -RRB-)))
    (VP
      (VP (VBD:[1286..1293] blunted)
        (NP
          (NP
            (ADJP (NN:[1294..1297] ACh)
              (ADJP-1 (-NONE-:[1297..1297] *P*)))
            (NML-2 (-NONE-:[1297..1297] *P*)))
          (CC:[1298..1301] and)
          (NP
            (ADJP (NN:[1302..1311] histamine)
              (ADJP-1 (VBN:[1312..1320] mediated)))
            (NML-2 (NN:[1321..1325] EDHF) (NNS:[1326..1335] responses)))))
      (CC:[1336..1339] but)
      (VP (VBD:[1340..1343] did) (RB:[1344..1347] not)
        (VP (VB:[1348..1353] alter)
          (NP
            (NP (NN:[1354..1366] vasodilation))
            (VP (VBN:[1368..1377] initiated)
              (NP (-NONE-:[1377..1377] *))
              (PP (IN:[1378..1385] through)
                (NP
                  (NP
                    (NML (NN:[1386..1387] K) (SYM:[1387..1388] +))
                    (NN:[1389..1396] channel) (NN:[1397..1407] activation))
                  (PP
                    (PP (IN:[1408..1410] by)
                      (NP (CC:[1411..1417] either) (NN:[1418..1428] cromakalim)
                          (CC:[1429..1431] or) (NN:[1432..1439] NS-1619)))
                    (,:[1439..1440] ,) (CC:[1441..1443] or)
                    (PP (IN:[1445..1452] through)
                      (NP
                        (NP (DT:[1453..1456] the)
                          (NML
                            (NML (JJ:[1457..1463] nitric)
                                 (NN:[1464..1469] oxide))
                            (PP (HYPH:[1469..1470] -)
                              (NP (NN:[1470..1474] cGMP))))
                          (NN:[1475..1482] pathway))
                        (NP (-LRB-:[1483..1484] -LRB-)
                           (NN:[1484..1490] sodium)
                           (NN:[1491..1504] nitroprusside)
                          (-RRB-:[1504..1505] -RRB-))))))))))))
    (.:[1505..1506] .)))

;sentence 9 Span:1507..1688
;Clotrimazole, an  imidazole that inhibits CYP by binding to the heme moiety,
;attenuated ACh,  histamine, and cromakalim but not sodium
;nitroprusside-mediated vasodilator  responses.
;[1507..1519]:substance:"Clotrimazole"
;[1525..1534]:substance:"imidazole"
;[1549..1552]:cyp450:"CYP"
;[1571..1575]:substance:"heme"
;[1595..1598]:substance:"ACh"
;[1601..1610]:substance:"histamine"
;[1616..1626]:substance:"cromakalim"
;[1635..1655]:substance:"sodium nitroprusside"
;[1665..1676]:substance:"vasodilator"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1507..1519] Clotrimazole))
      (,:[1519..1520] ,)
      (NP
        (NP (DT:[1521..1523] an) (NN:[1525..1534] imidazole))
        (SBAR
          (WHNP-1 (WDT:[1535..1539] that))
          (S
            (NP-SBJ-1 (-NONE-:[1539..1539] *T*))
            (VP (VBZ:[1540..1548] inhibits)
              (NP (NN:[1549..1552] CYP))
              (PP-MNR (IN:[1553..1555] by)
                (NP
                  (NP (VBG:[1556..1563] binding))
                  (PP (TO:[1564..1566] to)
                    (NP (DT:[1567..1570] the) (NN:[1571..1575] heme)
                        (NN:[1576..1582] moiety))))))))))
    (,:[1582..1583] ,)
    (VP
      (VP (VBD:[1584..1594] attenuated)
        (NP=2
          (NP (NN:[1595..1598] ACh)
            (NML-3 (-NONE-:[1598..1598] *P*)))
          (,:[1598..1599] ,)
          (NP (NN:[1601..1610] histamine)
            (NML-3 (-NONE-:[1610..1610] *P*)))
          (,:[1610..1611] ,) (CC:[1612..1615] and)
          (NP (NN:[1616..1626] cromakalim)
            (NML-3 (-NONE-:[1626..1626] *P*)))))
      (CONJP (CC:[1627..1630] but) (RB:[1631..1634] not))
      (VP
        (NP=2
          (NML
            (ADJP
              (NML (NN:[1635..1641] sodium) (NN:[1642..1655] nitroprusside))
              (HYPH:[1655..1656] -) (VBN:[1656..1664] mediated))
            (NN:[1665..1676] vasodilator))
          (NML-3 (NNS:[1678..1687] responses)))))
    (.:[1687..1688] .)))

;sentence 10 Span:1689..1938
;Other CYP isozyme selective inhibitors, such as metyrapone (CYP 2B), 
;7-pentoxyresorufin (CYP 2B1), sulfaphenazole (CYP 2C/3A), and 17-octadecynoic
; acid (4A-linked omega-hydroxylase inhibitor), did not alter ACh or 
;histamine-induced EDHF response.
;[1695..1706]:cyp450:"CYP isozyme"
;[1717..1727]:substance:"inhibitors"
;[1737..1747]:substance:"metyrapone"
;[1749..1755]:cyp450:"CYP 2B"
;[1759..1777]:substance:"7-pentoxyresorufin"
;[1779..1786]:cyp450:"CYP 2B1"
;[1789..1803]:substance:"sulfaphenazole"
;[1805..1811]:cyp450:"CYP 2C"
;[1805..1808]...[1812..1814]:cyp450:"CYP"..."3A"
;[1821..1842]:substance:"17-octadecynoic  acid"
;[1844..1846]:cyp450:"4A"
;[1854..1871]:cyp450:"omega-hydroxylase"
;[1872..1881]:substance:"inhibitor"
;[1898..1901]:substance:"ACh"
;[1906..1915]:substance:"histamine"
;[1924..1928]:substance:"EDHF"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1689..1694] Other)
        (NML (NN:[1695..1698] CYP) (NN:[1699..1706] isozyme))
        (JJ:[1707..1716] selective) (NNS:[1717..1727] inhibitors))
      (,:[1727..1728] ,)
      (PP (JJ:[1729..1733] such) (IN:[1734..1736] as)
        (NP
          (NP
            (NP (NN:[1737..1747] metyrapone))
            (NP (-LRB-:[1748..1749] -LRB-)
               (NN:[1749..1752] CYP) (NN:[1753..1755] 2B)
              (-RRB-:[1755..1756] -RRB-)))
          (,:[1756..1757] ,)
          (NP
            (NP (NN:[1759..1777] 7-pentoxyresorufin))
            (NP (-LRB-:[1778..1779] -LRB-)
               (NN:[1779..1782] CYP) (NN:[1783..1786] 2B1)
              (-RRB-:[1786..1787] -RRB-)))
          (,:[1787..1788] ,)
          (NP
            (NP (NN:[1789..1803] sulfaphenazole))
            (NP (-LRB-:[1804..1805] -LRB-)
              (NP
                (NML-1 (NN:[1805..1808] CYP))
                (NN:[1809..1811] 2C))
              (SYM:[1811..1812] /)
              (NP
                (NML-1 (-NONE-:[1812..1812] *P*))
                (NN:[1812..1814] 3A))
              (-RRB-:[1814..1815] -RRB-)))
          (,:[1815..1816] ,) (CC:[1817..1820] and)
          (NP
            (NP (JJ:[1821..1836] 17-octadecynoic) (NN:[1838..1842] acid))
            (NP (-LRB-:[1843..1844] -LRB-)
              (ADJP (NN:[1844..1846] 4A) (HYPH:[1846..1847] -)
                    (VBN:[1847..1853] linked))
              (NN:[1854..1871] omega-hydroxylase) (NN:[1872..1881] inhibitor)
               (-RRB-:[1881..1882] -RRB-))))))
    (,:[1882..1883] ,)
    (VP (VBD:[1884..1887] did) (RB:[1888..1891] not)
      (VP (VB:[1892..1897] alter)
        (NP
          (NP (NN:[1898..1901] ACh))
          (CC:[1902..1904] or)
          (NP
            (ADJP (NN:[1906..1915] histamine) (HYPH:[1915..1916] -)
                  (VBN:[1916..1923] induced))
            (NN:[1924..1928] EDHF) (NN:[1929..1937] response)))))
    (.:[1937..1938] .)))

;sentence 11 Span:1939..2114
;The EDHF-mediated dilations initiated by ACh  and histamine, as well as
;K(ATP) activation by cromakalim, were blocked by  mepacrine, a nonselective
;phospholipase A2 inhibitor.
;[1943..1947]:substance:"EDHF"
;[1980..1983]:substance:"ACh"
;[1989..1998]:substance:"histamine"
;[2011..2012]:substance:"K"
;[2013..2016]:substance:"ATP"
;[2032..2042]:substance:"cromakalim"
;[2061..2070]:substance:"mepacrine"
;[2087..2103]:substance:"phospholipase A2"
;[2104..2113]:substance:"inhibitor"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (DT:[1939..1942] The)
          (ADJP (NN:[1943..1947] EDHF) (HYPH:[1947..1948] -)
                (VBN:[1948..1956] mediated))
          (NNS:[1957..1966] dilations))
        (VP (VBN:[1967..1976] initiated)
          (NP (-NONE-:[1976..1976] *))
          (PP (IN:[1977..1979] by)
            (NP-LGS (NN:[1980..1983] ACh) (CC:[1985..1988] and)
                    (NN:[1989..1998] histamine)))))
      (,:[1998..1999] ,)
      (CONJP (RB:[2000..2002] as) (RB:[2003..2007] well) (IN:[2008..2010] as))
      (NP
        (NP (NN:[2011..2012] K)
          (PRN (-LRB-:[2012..2013] -LRB-)
            (NP (NN:[2013..2016] ATP))
            (-RRB-:[2016..2017] -RRB-))
          (NN:[2018..2028] activation))
        (PP (IN:[2029..2031] by)
          (NP (NN:[2032..2042] cromakalim))))
      (,:[2042..2043] ,))
    (VP (VBD:[2044..2048] were)
      (VP (VBN:[2049..2056] blocked)
        (NP-1 (-NONE-:[2056..2056] *))
        (PP (IN:[2057..2059] by)
          (NP-LGS
            (NP (NN:[2061..2070] mepacrine))
            (,:[2070..2071] ,)
            (NP (DT:[2072..2073] a) (JJ:[2074..2086] nonselective)
              (NML (NN:[2087..2100] phospholipase) (NN:[2101..2103] A2))
              (NN:[2104..2113] inhibitor))))))
    (.:[2113..2114] .)))

;sentence 12 Span:2115..2177
;Mepacrine did not alter  K(Ca) activation by compound NS-1619.
;[2115..2124]:substance:"Mepacrine"
;[2140..2141]:substance:"K"
;[2142..2144]:substance:"Ca"
;[2160..2168]:substance:"compound"
;[2169..2176]:substance:"NS-1619"
(SENT
  (S
    (NP-SBJ (NN:[2115..2124] Mepacrine))
    (VP (VBD:[2125..2128] did) (RB:[2129..2132] not)
      (VP (VB:[2133..2138] alter)
        (NP
          (NP (NN:[2140..2141] K)
            (PRN (-LRB-:[2141..2142] -LRB-)
              (NP (NN:[2142..2144] Ca))
              (-RRB-:[2144..2145] -RRB-))
            (NN:[2146..2156] activation))
          (PP (IN:[2157..2159] by)
            (NP (NN:[2160..2168] compound) (NN:[2169..2176] NS-1619))))))
    (.:[2176..2177] .)))

;sentence 13 Span:2178..2598
;I conclude that 1) the isolated perfused  rat mesenteric prearteriolar bed
;releases in response to ACh and histamine, an  EDHF that causes vasodilation
;through K+ channel activation; 2) the EDHF is most  likely a CYP-derived
;arachidonate product; 3) CYP 1A is well suited as the  isozyme responsible
;for EDHF production in this vascular bed; and 4) PLA2  appears to mediate the
;release of the precursor arachidonic acid.
;[2277..2280]:substance:"ACh"
;[2285..2294]:substance:"histamine"
;[2300..2304]:substance:"EDHF"
;[2338..2340]:substance:"K+"
;[2368..2372]:substance:"EDHF"
;[2391..2394]:cyp450:"CYP"
;[2403..2415]:substance:"arachidonate"
;[2416..2423]:substance:"product"
;[2428..2434]:cyp450:"CYP 1A"
;[2458..2465]:cyp450:"isozyme"
;[2482..2486]:substance:"EDHF"
;[2527..2531]:substance:"PLA2"
;[2571..2580]:substance:"precursor"
;[2581..2597]:substance:"arachidonic acid"
(SENT
  (S
    (NP-SBJ (PRP:[2178..2179] I))
    (VP (VBP:[2180..2188] conclude)
      (SBAR (IN:[2189..2193] that)
        (S
          (S
            (LST (LS:[2194..2196] 1-RRB-))
            (NP-SBJ (DT:[2197..2200] the) (JJ:[2201..2209] isolated)
                    (JJ:[2210..2218] perfused) (NN:[2220..2223] rat)
                    (JJ:[2224..2234] mesenteric) (JJ:[2235..2248] prearteriolar)
                    (NN:[2249..2252] bed))
            (VP (VBZ:[2253..2261] releases)
              (PP (IN:[2262..2264] in)
                (NP
                  (NP (NN:[2265..2273] response))
                  (PP (TO:[2274..2276] to)
                    (NP
                      (NP (NN:[2277..2280] ACh))
                      (CC:[2281..2284] and)
                      (NP
                        (NP (NN:[2285..2294] histamine))
                        (,:[2294..2295] ,)
                        (NP
                          (NP (DT:[2296..2298] an) (NN:[2300..2304] EDHF))
                          (SBAR
                            (WHNP-1 (WDT:[2305..2309] that))
                            (S
                              (NP-SBJ-1 (-NONE-:[2309..2309] *T*))
                              (VP (VBZ:[2310..2316] causes)
                                (NP (NN:[2317..2329] vasodilation))
                                (PP-MNR (IN:[2330..2337] through)
                                  (NP
                                    (NML (NN:[2338..2339] K)
                                         (SYM:[2339..2340] +))
                                    (NN:[2341..2348] channel)
                                     (NN:[2349..2359] activation))))))))))))))
          (::[2359..2360] ;)
          (S
            (LST (LS:[2361..2363] 2-RRB-))
            (NP-SBJ (DT:[2364..2367] the) (NN:[2368..2372] EDHF))
            (VP (VBZ:[2373..2375] is)
              (ADVP (RBS:[2376..2380] most) (JJ:[2382..2388] likely))
              (NP-PRD (DT:[2389..2390] a)
                (ADJP (NN:[2391..2394] CYP) (HYPH:[2394..2395] -)
                      (VBN:[2395..2402] derived))
                (NN:[2403..2415] arachidonate) (NN:[2416..2423] product))))
          (::[2423..2424] ;)
          (S
            (LST (LS:[2425..2427] 3-RRB-))
            (NP-SBJ (NN:[2428..2431] CYP) (NN:[2432..2434] 1A))
            (VP (VBZ:[2435..2437] is)
              (ADJP-PRD (RB:[2438..2442] well) (JJ:[2443..2449] suited)
                (PP (IN:[2450..2452] as)
                  (NP
                    (NP (DT:[2453..2456] the) (NN:[2458..2465] isozyme))
                    (ADJP (JJ:[2466..2477] responsible)
                      (PP (IN:[2478..2481] for)
                        (NP (NN:[2482..2486] EDHF) (NN:[2487..2497] production))))
                    (PP-LOC (IN:[2498..2500] in)
                      (NP (DT:[2501..2505] this) (JJ:[2506..2514] vascular)
                          (NN:[2515..2518] bed))))))))
          (::[2518..2519] ;) (CC:[2520..2523] and)
          (S
            (LST (LS:[2524..2526] 4-RRB-))
            (NP-SBJ (NN:[2527..2531] PLA2))
            (VP (VBZ:[2533..2540] appears)
              (S
                (NP-SBJ (-NONE-:[2540..2540] *))
                (VP (TO:[2541..2543] to)
                  (VP (VB:[2544..2551] mediate)
                    (NP
                      (NP (DT:[2552..2555] the) (NN:[2556..2563] release))
                      (PP (IN:[2564..2566] of)
                        (NP
                          (NP (DT:[2567..2570] the) (NN:[2571..2580] precursor))
                          (NP (JJ:[2581..2592] arachidonic)
                              (NN:[2593..2597] acid)))))))))))))
    (.:[2597..2598] .)))

;section 14 Span:2602..2646
;PMID: 9234831 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2602..2606] PMID) (::[2606..2607] :) (CD:[2608..2615] 9234831)
        (NN:[2616..2617] -LSB-) (NNP:[2617..2623] PubMed) (::[2624..2625] -)
        (NN:[2626..2633] indexed) (IN:[2634..2637] for)
        (NNP:[2638..2646] MEDLINE-RSB-)))
